Skin infection management using novel antibacterial agents
- PMID: 24312843
- PMCID: PMC3846056
- DOI: 10.5681/apb.2013.040
Skin infection management using novel antibacterial agents
Abstract
Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) cause difficulties in the management of skin and soft tissue infections and have led to morbidity and mortality in hospital-acquired infections especially in susceptible individuals, those who are generally sick or immunosuppressed. Currently approaches in antibacterial agents offer opportunities to manage the trouble using novel anti-infection systems. Therefore, nanotechnology, a most promising field for generating new applications in medicine, has introduced a most prominent nanoproduct named as nanosilver that revealed excellent antimicrobial activity against some of the hazardous infections. Also cathelicidin peptides which are a part of native immune defense system in the skin and epithelia exhibit excellent antimicrobial activity against some of these perilous infections.
Keywords: Antibiotic Resistance; Cathelicidin; Infection; Nanosilver.
References
-
- Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant staphylococcus aureus (MRSA) Int J Antimicrob Agents . 2007;30(5):398–408. - PubMed
-
- Sanchez Garcia M, De la Torre, Morales G, Pelaez B, Tolon MJ, Domingo S. et al. Clinical outbreak of linezolid-resistant staphylococcus aureus in an intensive care unit. JAMA . 2010;303(22):2260–4. - PubMed
-
- Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents . 2006; 27:87–96. - PubMed
-
- Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol . 2001;9(1):34–9. - PubMed
LinkOut - more resources
Full Text Sources